United Kingdom Lipid Disorder Therapeutics Market Insight
The United Kingdom Lipid Disorder Therapeutics Market is growing at an 13.1%CAGR, driven by cardiovascular disease burden, statins, biologics use, NHS support, and improved lipid therapies.
United Kingdom Lipid Disorder Therapeutics Market Insights Forecasts to 2035
- The United KingdomLipid Disorder Therapeutics Market Size Was Estimated at USD 20.65Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 13.1% from 2025 to 2035
- The United Kingdom Lipid Disorder Therapeutics Market Size is Expected to Reach USD 70.9Million by 2035
Notable Insights for United Kingdom Lipid Disorder Therapeutics Market
- By drug class, statins dominate with approximately 55–65% share due to strong efficacy in lowering LDL cholesterol and widespread NHS prescribing.
- PCSK9 inhibitors account for a growing 10–15% share, driven by use in high-risk and statin-intolerant patients.
- Around 30–40% of UK adults with dyslipidemia remain on long-term lipid-lowering therapy, reflecting high disease prevalence and preventive treatment focus.
- Nearly 60–70% of treated patients achieve improved LDL-C control with combination therapies, compared to monotherapy approaches.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Lipid Disorder Therapeutics Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Lipid Disorder Therapeutics Market
- Pfizer
- AstraZeneca
- Novartis
- Amgen
- Sanofi
- Merck & Co.
- Daiichi Sankyo
- Viatris
- Others
Recent Developments:
- In June 2025, Buckinghamshire NHS Trust expanded its Lipid Accelerator Programmed, using population health analytics and British Heart Foundation funding to identify high-risk patients needing advanced lipid-lowering therapies across NHS pathways.
- In March 2025, Inclisiran (Leqvio) expanded NHS access, strengthening lipid disorder management by targeting PCSK9 inhibition, improving LDL-C reduction in statin-intolerant patients, and supporting long-term cardiovascular risk reduction across UK care pathways.
Market Segmentation:
United Kingdom Lipid Disorder Therapeutics Market, By Drug Class
- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Fibrates
- Others
United Kingdom Lipid Disorder Therapeutics Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Centers
United Kingdom Lipid Disorder Therapeutics Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Lipid Disorder Therapeutics Market is expected to grow steadily due to rising cardiovascular disease prevalence and strong preventive healthcare initiatives under the NHS. Experts highlight that statins will continue to dominate, while biologics such as PCSK9 inhibitors will drive future growth. Increasing adoption of combination therapies, improved diagnostic screening, and advancements in targeted lipid-lowering drugs are expected to significantly enhance treatment outcomes and support market expansion through 2035.